Oncology & Cancer

Study identifies new potential target in glioblastoma

Researchers are hopeful that new strategies could emerge for slowing the growth and recurrence of the most common primary brain cancer in adults, glioblastoma, based on the results of a study published today in Cancer Research.

Oncology & Cancer

New vaccine strategy boosts T-cell therapy

A promising new way to treat some types of cancer is to program the patient's own T cells to destroy the cancerous cells. This approach, termed CAR-T cell therapy, is now used to combat some types of leukemia, but so far ...

Oncology & Cancer

Tumor-treating fields in glioblastoma: Indication of a benefit

Glioblastoma is an aggressive brain tumor that usually occurs in late adulthood. Just two years after diagnosis, only 13.6 percent of patients are still alive. Standard treatment consists of surgery, followed by radiation ...

Oncology & Cancer

Scientists track brain tumor turncoats with advanced imaging

Glioblastomas, the deadliest type of brain tumor in adults, attract "turncoats." These are macrophages, a type of immune cell, which promote tumor progression and mask tumors from the immune system's scrutiny. To better understand ...

Oncology & Cancer

A clear vision for cancer diagnosis

While reading an article about Sen. John McCain's glioblastoma diagnosis, Kavya Kopparapu was shocked to learn that the prognosis for this aggressive brain cancer has not improved over the past 30 years. With standard treatment, ...

Oncology & Cancer

Scientists discover molecular key to how cancer spreads

Yale researchers have discovered how metastasis, the spread of cancer cells throughout the body, is triggered on the molecular level, and have developed a tool with the potential to detect those triggers in patients with ...

Oncology & Cancer

Cancer-fighting combination targets glioblastoma

Researchers have paired a specialized diet and a tumor-fighting drug and found the non-toxic combination helps to destroy the two major cells found in an aggressive form of brain cancer, the team reports in the online edition ...

Oncology & Cancer

Researchers test novel gene therapy for glioblastoma

A novel gene therapy clinical trial at University Hospitals Seidman Cancer Center and the Case Comprehensive Cancer Center is showing promising results, garnering funding with a prestigious U01 Grant from the National Cancer ...

page 1 from 23

Glioblastoma multiforme (GBM) is the most common and most aggressive malignant primary brain tumor in humans, involving glial cells and accounting for 52% of all functional tissue brain tumor cases and 20% of all intracranial tumors. Despite being the most prevalent form of primary brain tumor, GBMs occur in only 2–3 cases per 100,000 people in Europe and North America. According to the WHO classification of the tumors of the central nervous system‎, the standard name for this brain tumor is "glioblastoma"; it presents two variants: giant cell glioblastoma and gliosarcoma. Glioblastomas are also an important brain tumor in canines, and research continues to use this as a model for developing treatments in humans.

Treatment can involve chemotherapy, radiation, radiosurgery, corticosteroids, antiangiogenic therapy, surgery and experimental approaches such as gene transfer.

With the exception of the brainstem gliomas, glioblastoma has the worst prognosis of any central nervous system (CNS) malignancy, despite multimodality treatment consisting of open craniotomy with surgical resection of as much of the tumor as possible, followed by concurrent or sequential chemoradiotherapy, antiangiogenic therapy with bevacizumab, gamma knife radiosurgery, and symptomatic management with corticosteroids. Prognosis is poor, with a median survival time of approximately 14 months.

This text uses material from Wikipedia licensed under CC BY-SA